newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

Enhanced the company's portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a bifunctional IL-2 and TGF-B program targeting